The beta3 adrenergic receptor has been proposed to be a therapeutic target for the treatment of obesity and adult-onset diabetes, yet very little is known about the biochemical and pharmacological properties of these receptors. Pharmacological and molecular data indicate that adipose tissues contain both beta1 and beta3 receptors, yet it is unclear why fat cells make both receptor subtypes. Our preliminary data, however, indicate that beta1 and beta3 receptors have distinct signal- transducing properties and are differentially regulated by agonist exposure. We propose to further characterize these differences and examine the molecular bases of those differences. We have discovered that he human beta3 receptor gene contains an intron and a second protein-coding exon. All previous work with the recombinant human beta3 receptor was conducted on a protein that lacked the sequence from the second exon, and thus was incomplete. Furthermore, preliminary data indicates that the newly-discovered exon may play an important role in the pharmacological and regulatory properties of the human receptor. We have also discovered that the rat beta3 receptor gene also contains multiple exons and introns. The sequence of the first intron of the rat gene suggest that it may play a role in fat-specific expression.
Our specific aims are: 1. To characterize, for the first time, the pharmacological properties of the recombinant full-length human beta3 receptor. To further characterize the differential signalling properties of beta1 and beta 3 receptors. 2. To characterize the differential regulation of beta1 and beta3 receptors by agonist exposure and to examine the molecular basis. 3. To evaluate the impact of the differential signalling properties of beta1 and beta3 receptors on physiological responses in adipocytes. 4. To determine the genetic elements that confer adipose tissue-specific expression of the rat beta3 receptor, with a initial focus on the potential role of the first intron. To determine whether the human beta3 receptor gene contains similar elements.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK046339-01A1
Application #
2145519
Study Section
Endocrinology Study Section (END)
Project Start
1993-12-01
Project End
1997-11-30
Budget Start
1993-12-01
Budget End
1994-11-30
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Wayne State University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Granneman, J G (2001) The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280:E199-202
Sacchetti, P; Mitchell, T R; Granneman, J G et al. (2001) Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 76:1565-72
Konkar, A A; Zhai, Y; Granneman, J G (2000) beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol Pharmacol 57:252-8
Konkar, A A; Zhu, Z; Granneman, J G (2000) Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors. J Pharmacol Exp Ther 294:923-32
Burchett, S A; Bannon, M J; Granneman, J G (1999) RGS mRNA expression in rat striatum: modulation by dopamine receptors and effects of repeated amphetamine administration. J Neurochem 72:1529-33
Sacchetti, P; Brownschidle, L A; Granneman, J G et al. (1999) Characterization of the 5'-flanking region of the human dopamine transporter gene. Brain Res Mol Brain Res 74:167-74
Granneman, J G; Zhai, Y; Zhu, Z et al. (1998) Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene. Mol Pharmacol 54:687-94
Granneman, J G; Lahners, K N; Zhai, Y (1998) Agonist interactions with chimeric and mutant beta1- and beta3-adrenergic receptors: involvement of the seventh transmembrane region in conferring subtype specificity. Mol Pharmacol 53:856-61
Chaudhry, A; Granneman, J G (1997) Effect of hypothyroidism on adenylyl cyclase activity and subtype gene expression in brown adipose tissue. Am J Physiol 273:R762-7
Chaudhry, A; Muffler, L A; Yao, R et al. (1996) Perinatal expression of adenylyl cyclase subtypes in rat brown adipose tissue. Am J Physiol 270:R755-60

Showing the most recent 10 out of 13 publications